What did @alejandrajesusrod actually say?
She documented her first Wegovy injection, starting at 230 lbs with a goal weight of 138 lbs. She walked through her anxiety about needles, sanitized her injection site, and followed what appears to be the standard auto-injector technique: pinch the skin, press the device, hold through two clicks, and count to ten. "You do feel that quick pinch," she said, adding that her nerves probably made it feel worse than it was.
There were no outlandish claims here. No promises of rapid weight loss. No advice about dosing. She didn't tell anyone what to expect medically. This was a first-person documentation of a first injection, and that's largely what it stayed.
Does the science back this up?
The injection technique she demonstrated aligns with Novo Nordisk's prescribing information for the Wegovy auto-injector, and the physiological experience she described, a brief pinch followed by mild discomfort, is consistent with what clinical trial participants reported. So yes, the limited claims she made hold up.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults using semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks. Her goal of reaching 138 lbs from 230 lbs would represent roughly a 40% reduction, which is well beyond what clinical evidence supports for most patients on semaglutide alone. That math deserves a closer look, even if she didn't explicitly claim the drug would get her there.
The hold-for-ten-seconds instruction she followed is consistent with guidance for subcutaneous auto-injectors to ensure full dose delivery and minimize leakage at the injection site.
What did they get wrong (or right)?
She got the mechanics right. The two-click method, counting to ten, pinching the skin, sanitizing first. These are correct steps for the Wegovy pen, and showing them accurately to 17,000 viewers is genuinely useful.
What she didn't address, though she wasn't obligated to in a Day 1 video, is her weight loss target. A 92-lb loss from semaglutide alone would be exceptional, bordering on outside the typical clinical range. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed sustained weight loss of about 15% over two years. For someone starting at 230 lbs, that's roughly 34 lbs, not 92. That gap matters if viewers are setting their own expectations based on her stated goal.
To be fair, she never said Wegovy would get her to 138. She stated a goal. Those are different things. But in a TikTok ecosystem where weight loss drug content often overpromises, passive goal-setting still shapes audience expectations.
What should you actually know?
First-injection anxiety is real and normal. Subcutaneous injections with auto-injectors are designed to minimize pain, and the brief discomfort she described is typical. Her emotional honesty here, "I'm very scared, not a needle person at all," is probably more relatable and more helpful to new users than a clinical instructional video would be.
What viewers should not take from this video is a roadmap for weight loss outcomes. Semaglutide works differently for different people. Factors including baseline metabolic health, concurrent lifestyle changes, and whether someone titrates through the full dose schedule all affect results. The FDA-approved dose for Wegovy is 2.4 mg weekly, reached through a 16-week titration starting at 0.25 mg. What dose she's starting at isn't specified in the video.
Side effects, which she didn't mention, are common in the first weeks. Nausea affects a significant portion of users early in treatment. The STEP trials reported gastrointestinal side effects in over 40% of participants (Wilding et al., 2021, NEJM). First-week content that skips this sets up viewers for surprise, not safety.
Bottom line
This video is a low-risk, first-person experience post with accurate injection technique and honest emotional content. The goal weight she mentioned is more ambitious than what the clinical data typically supports, but she didn't attribute that target to the drug. The bigger gap in content like this is what comes after week one. Technique matters, but so does knowing what to expect when the nausea hits on week three.